Purdue Pharma, US states agree to new opioid settlement

New Delhi: Purdue Pharma reached a nationwide settlement Thursday over its role in the opioid crisis, with the Sackler family members who own the company boosting their cash contribution to as much as $6 billion in a deal intended to staunch a flood of lawsuits facing the maker of OxyContin.

The deal follows an earlier settlement that had been appealed by eight states and the District of Columbia. They agreed to sign on after the Sacklers kicked in more cash and accepted other terms. In exchange, the family would be protected from civil lawsuits.

Also Read:Purdue Pharma seeks to appeal US ruling that overturned its opioid settlement

In all, the plan could be worth more than $10 billion over time. It calls for members of the Sackler family to give up control of the Stamford, Connecticut-based company so it can be turned into a new entity with profits used to fight the crisis. The deal would not shield members of the family from criminal charges, although there's no indication any are forthcoming.

Sackler family members have not unequivocally offered an apology but issued a statement of regret about the toll of OxyContin, its signature painkiller, which users learned could be manipulated to produce quick highs. Purdue Pharma had promoted its use for a broad range of pain issues for which doctors previously had shied away from prescribing opioids.

"While the families have acted lawfully in all respects, they sincerely regret that OxyContin, a prescription medicine that continues to help people suffering from chronic pain, unexpectedly became part of an opioid crisis that has brought grief and loss to far too many families and communities," said the statement from the Sackler family.

Under the settlement, victims also are to have a forum in court, by videoconference scheduled for March 9, to address some of the Sacklers. That's something they have not been able to do previously in a public setting.

The settlement is outlined in a report filed in U.S. Bankruptcy Court in White Plains, New York, and must be approved by the judge. It was hammered out with attorneys general from the eight states — California, Connecticut, Delaware, Maryland, Oregon, Rhode Island, Vermont and Washington — and D.C. who had opposed the earlier one, arguing that it did not properly hold Sackler family members accountable.

Several parents whose children became addicted to opioids said they were ambivalent — glad that more money will be available for addiction treatment, but upset that the Sacklers will remain wealthy and escape more accountability.

Connecticut's Paige Niver, whose daughter became addicted following a bicycle accident when she was 14 and remains in recovery about 13 years later, said she didn't want other families to endure what hers did.

"As a mother, I did what the doctor told me to do and I just kept giving them to her. And when they were starting to have kind of a lesser effect, they say, 'Oh, then you need to give her more.' And that's exactly what I did," she said at a news conference Thursday with her state's attorney general.

"I never thought I'd see any justice for it, so the money will do so much good — fund as much treatment and prevention as possible," Niver said.

Ed Bisch, whose 18-year-old son died of an overdose 20 years ago, is glad states pushed Sackler family members to pay more. Still, he called the settlement "a horrible deal" because so many parents who buried loved ones won't see money, while the Sacklers retain their wealth.

"Guess what? They still made billions and billions of dollars," said Bisch, of Westampton, New Jersey. "Without any jail time, where is the deterrent? We've lost two generations to their greed."

Individual victims and their survivors are to share a $750 million fund, a key provision not found in other opioid settlements. About 149,000 people made claims in advance and could qualify for shares from the fund.

That amount is unchanged in the new plan, but states will be able to create funds they can use to compensate victims beyond that, if they choose.

Other new provisions include an agreement from Sackler family members that they won't fight when institutions attempt to take their names off buildings funded by the family's support. And additional company documents are to be made public.

Most of the the money is to flow to state and local governments, Native American tribes, and some hospitals, with the requirement that it be used to battle an opioid crisis that has been linked to more than 500,000 deaths in the U.S. over the past two decades.

"We're pleased with the settlement achieved in mediation, under which all of the additional settlement funds will be used for opioid abatement programs, overdose rescue medicines, and victims," Purdue Pharma said in a statement issued separately from the family's. "With this mediation result, we continue on track to proceed through the appeals process on an expedited schedule, and we hope to swiftly deliver these resources."

Kentucky and Oklahoma are not part of the deal because they both reached previous settlements with Purdue.

Purdue, the originator of time-release versions of powerful prescription painkillers, is the highest-profile company out of many that have faced lawsuits over the crisis. It has twice pleaded guilty to criminal charges related to its business practices around OxyContin.

The latest announcement follows another landmark settlement late last week, when drugmaker Johnson & Johnson and three distributors finalized a settlement that will send $26 billion over time to virtually every state and local governments throughout the U.S.

There are two key differences between the latest Purdue settlement and the previous one struck last year. The Sacklers' cash contribution has gone up by at least $1.2 billion, and state attorneys general and the District of Columbia have now agreed.

The money is to begin flowing after Purdue, which is to be renamed Knoa Pharma, emerges from bankruptcy. It's not clear when that will be. The last payment under the settlement is not scheduled to be made until 2039.

Last year, the eight states and D.C. refused to sign on, and then most of them appealed after the deal was approved by the bankruptcy judge.

In December, a U.S. district judge sided with the nine holdouts. The judge, Colleen McMahon, rejected the settlement with a finding that bankruptcy judges lack the authority to grant legal protection to people who don't themselves file for bankruptcy when some parties disagree.

Purdue appealed that decision, which, if left standing, could have scuttled a common method of reaching settlements in sweeping, complicated lawsuits.

The attorneys general who have signed on are dropping from the main legal battle but are still free to write briefs to tell courts not to allow the protections for people who do not file for bankruptcy themselves.

Connecticut Attorney General William Tong has repeatedly said he has felt a "special obligation to be aggressive" in the case because Purdue is headquartered in the state. He expressed some disappointment Thursday with the final settlement, even though he said it was 40% more than the previous one.

"I wanted more. I still want more. But I took it as far as I could take it," he said during a news conference. "If we were to continue, we would do it alone and that is untenable."

The new settlement requires approval from U.S Bankruptcy Judge Robert Drain. Appeals related to the previous version of the plan could continue moving through the court system.

Also Read:Purdue Pharma judge rejects call to halt opioid deal